Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated:  1/14/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated: 1/14/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated:  1/14/2016
Florida Cancer Center
mi
from
Sarasota, FL
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated: 1/14/2016
Florida Cancer Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated:  1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status: Enrolling
Updated: 1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated:  1/19/2016
University of Chicago
mi
from
Chicago, IL
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated: 1/19/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated:  1/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated: 1/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated:  1/19/2016
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated: 1/19/2016
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated:  1/19/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated: 1/19/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated:  1/19/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status: Enrolling
Updated: 1/19/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Status: Enrolling
Updated:  1/21/2016
Abramson Cancer Center of the Universirty of Pennsylvania
mi
from
Philadelphia, PA
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Status: Enrolling
Updated: 1/21/2016
Abramson Cancer Center of the Universirty of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  1/22/2016
UTHealth Memorial Hermann Cancer Center
mi
from
Houston, TX
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 1/22/2016
UTHealth Memorial Hermann Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Alta Dermatology
mi
from
Mesa, AZ
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Alta Dermatology
mi
from
Mesa, AZ
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Dermatology Specialists, Inc.
mi
from
Oceanside, CA
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Dermatology Specialists, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Colorado Medical Research Center
mi
from
Denver, CO
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Colorado Medical Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Advanced Dermatology and Cosmetic Surgery
mi
from
Clermont, FL
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Advanced Dermatology and Cosmetic Surgery
mi
from
Clermont, FL
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Park Avenue Dermatology
mi
from
Orange Park, FL
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Minnesota Clinical Studies Center
mi
from
Fridley, MN
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Minnesota Clinical Studies Center
mi
from
Fridley, MN
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Derm Associates of Rochester
mi
from
Rochester, NY
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Derm Associates of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated:  1/22/2016
Rivergate Dermatology and Skin Care Center
mi
from
Goodlettsville, TN
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.
Status: Enrolling
Updated: 1/22/2016
Rivergate Dermatology and Skin Care Center
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated:  1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated: 1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  1/24/2016
University of Florida Shands Cancer Centre
mi
from
Gainesville, FL
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 1/24/2016
University of Florida Shands Cancer Centre
mi
from
Gainesville, FL
Click here to add this to my saved trials
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  1/24/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 1/24/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  1/24/2016
Liverpool Hospital
mi
from
Liverpool,
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 1/24/2016
Liverpool Hospital
mi
from
Liverpool,
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
La Mesa, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Oceanside, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Oxnard, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Pasadena, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Torrance, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Columbus, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Savannah, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Butte, MT
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Akron, OH
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated:  1/27/2016
Northside Hospital
mi
from
Atlanta, GA
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated: 1/27/2016
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated:  1/27/2016
University of Louisville
mi
from
Louisville, KY
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated: 1/27/2016
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated:  1/27/2016
Saint Louis University
mi
from
St. Louis, MO
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Status: Enrolling
Updated: 1/27/2016
Saint Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated:  1/27/2016
Sutter Health
mi
from
Santa Rosa, CA
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated: 1/27/2016
Sutter Health
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated:  1/27/2016
Elizabeth Liotta Dermatology
mi
from
Fredrick, MD
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated: 1/27/2016
Elizabeth Liotta Dermatology
mi
from
Fredrick, MD
Click here to add this to my saved trials
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated:  1/27/2016
University of Nevada
mi
from
Las Vegas, NV
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated: 1/27/2016
University of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated:  1/27/2016
South Carolina Skin Care Center
mi
from
Greenville, SC
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Status: Enrolling
Updated: 1/27/2016
South Carolina Skin Care Center
mi
from
Greenville, SC
Click here to add this to my saved trials
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/28/2016
H. Lee Moffitt Cancer Center (NSCLC)
mi
from
Tampa, FL
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/28/2016
H. Lee Moffitt Cancer Center (NSCLC)
mi
from
Tampa, FL
Click here to add this to my saved trials
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies
Status: Enrolling
Updated:  1/28/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies
Status: Enrolling
Updated: 1/28/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials